A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

NCT04285567 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG: Obinutuzumab
DRUG: Venetoclax
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Rituximab
DRUG: Bendamustine

Sponsor

Hoffmann-La Roche